Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Seladelpar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD known ✓ | Q03181 | 20/20 | 1.00 |
| ▸ | PPARA | Q07869 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seladelpar SCHEMBL392331 | 1.00 | PPARD (1.00) | PPARDPPARA | |
| Seladelpar SCHEMBL394392 | 1.00 | PPARD (1.00) | PPARDPPARA | |
| Seladelpar SCHEMBL29373526 | 1.00 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL3701620 | 0.94 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL16726808 | 0.94 | PPARD (0.88) | PPARDPPARA | |
| SCHEMBL3695586 | 0.93 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL377933 | 0.93 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL377934 | 0.93 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL3700528 | 0.93 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL3694382 | 0.92 | PPARD (1.00) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130331453-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-12 | — | — | US | claimed |
| EP-2100877-B1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-25 | — | — | EP | claimed |
| US-7301050-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICAL N.V. (BE) | 2007-11-27 | — | — | US | claimed |
| US-12364700-B2 | Medical use of pharmaceutical combination or composition | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-07-22 | — | — | US | disclosed |
| US-12312352-B2 | Use of a DPP-4 inhibitor in SIRS and/or sepsis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-05-27 | — | — | US | disclosed |
| US-20240299399-A1 | USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME | BOEHRINGER INGELHEIM INT (DE) | 2024-09-12 | — | — | US | disclosed |
| EP-4364796-A2 | USE OF LINAGLIPTIN IN CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY | Boehringer Ingelheim International GmbH (DE) | 2024-05-08 | — | — | EP | disclosed |
| US-11911387-B2 | Vasoprotective and cardioprotective antidiabetic therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20240033270-A1 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2024-02-01 | — | — | US | disclosed |
| US-20230381188-A1 | Medical Use of Pharmaceutical Combination or Composition | BOEHRINGER INGELHEIM INT (DE) | 2023-11-30 | — | — | US | disclosed |
| EP-4233840-A2 | COMBINATIONS OF LINAGLIPTIN AND METFORMIN | Boehringer Ingelheim International GmbH (DE) | 2023-08-30 | — | — | EP | disclosed |
| US-20080085927-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085927-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085927-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-7301050-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICAL N.V. (BE) | 2007-11-27 | — | — | US | disclosed |
| US-7301050-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICAL N.V. (BE) | 2007-11-27 | — | — | US | disclosed |
| US-7301050-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICAL N.V. (BE) | 2007-11-27 | — | — | US | disclosed |
| EP-1667964-A2 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| US-20050124698-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | CYMABAY THERAPEUTICS, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005042478-A2 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085927-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20050124698-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20240033270-A1 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY | DPP4, DPP3, DPP7 | PPARD 37/4885PPARA 83/4885 |
| US-11911387-B2 | Vasoprotective and cardioprotective antidiabetic therapy | DPP4, DPP3, DPP7 | PPARD 180/4885PPARA 345/4885 |
| US-20130331453-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-12312352-B2 | Use of a DPP-4 inhibitor in SIRS and/or sepsis | DPP4, DPP3, DPP7 | PPARD 638/4885PPARA 1125/4885 |
| US-20240299399-A1 | USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME | DPP4, DPP3, DPP7 | PPARD 251/4885PPARA 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.